Benchmark Maintains Speculative Buy on Anebulo Pharmaceuticals, Lowers Price Target to $8
Benchmark analyst Robert Wasserman maintains Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and lowers the price target from $10 to $8.
Anebulo Pharmaceuticals Q2 EPS $(0.15) Misses $(0.11) Estimate
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 200 percent decrease over losses of $(0.05) per
Acute Cannabinoid Intoxication: This Pharma Company’s Clinical Trials To Reduce And Treat Symptoms
Anebulo Pharmaceuticals, Inc.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Anebulo Pharmaceuticals Q1 EPS $(0.11) Down From $(0.07) YoY
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share. This is a 57.14 percent decrease over losses of $(0.07) per share from the same period last year.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 78 companies made new 52-week lows.
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
